Bayer, Broad Aim to Develop Therapeutics Targeting Cancer Genome Alterations | GenomeWeb

NEW YORK (GenomeWeb News) – Bayer Healthcare and the Broad Institute today announced a strategic alliance to jointly discover and develop therapeutic agents that target cancer genome alterations.

As part of the five-year deal, the partners will share their expertise on identifying and characterizing genes that are associated with cancer. They will also apply their screening platforms on compounds found in their libraries in order to identify those with potential as therapeutic agents.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.